CL2020000655A1 - Tratamiento mejorado de dermatitis atópica con tradipitant. - Google Patents

Tratamiento mejorado de dermatitis atópica con tradipitant.

Info

Publication number
CL2020000655A1
CL2020000655A1 CL2020000655A CL2020000655A CL2020000655A1 CL 2020000655 A1 CL2020000655 A1 CL 2020000655A1 CL 2020000655 A CL2020000655 A CL 2020000655A CL 2020000655 A CL2020000655 A CL 2020000655A CL 2020000655 A1 CL2020000655 A1 CL 2020000655A1
Authority
CL
Chile
Prior art keywords
tradipitant
atopic dermatitis
improved treatment
treatment
improved
Prior art date
Application number
CL2020000655A
Other languages
English (en)
Inventor
Changfu Xiao
Gunther Birznieks
Andrew Heitman
Sandra Smieszek
Mihael H Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CL2020000655A1 publication Critical patent/CL2020000655A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

LA DESCRIPCIÓN SE REFIERE A MÉTODOS MEJORADOS PARA EL TRATAMIENTO DE LA DERMATITIS ATÓPICA Y SUS SÍNTOMAS CON TRADIPITANT.
CL2020000655A 2017-09-13 2020-03-12 Tratamiento mejorado de dermatitis atópica con tradipitant. CL2020000655A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762558303P 2017-09-13 2017-09-13
US201762572456P 2017-10-14 2017-10-14

Publications (1)

Publication Number Publication Date
CL2020000655A1 true CL2020000655A1 (es) 2020-10-09

Family

ID=63684468

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000655A CL2020000655A1 (es) 2017-09-13 2020-03-12 Tratamiento mejorado de dermatitis atópica con tradipitant.

Country Status (12)

Country Link
US (1) US11549147B2 (es)
EP (1) EP3681505A1 (es)
JP (1) JP7347743B2 (es)
KR (1) KR20200054232A (es)
CN (1) CN111093671A (es)
AU (1) AU2018331267B2 (es)
BR (1) BR112020004964A2 (es)
CA (1) CA3073998A1 (es)
CL (1) CL2020000655A1 (es)
IL (1) IL272949A (es)
MX (1) MX2020002852A (es)
WO (1) WO2019055225A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6891385B2 (ja) * 2015-03-04 2021-06-18 バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． トラジピタントによる治療方法
CA3101210A1 (en) 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2021173641A1 (en) * 2020-02-25 2021-09-02 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
US20220328808A1 (en) 2020-05-07 2022-10-13 Lg Energy Solution, Ltd. High-nickel electrode sheet and method for manufacturing same
WO2023034718A1 (en) 2021-08-31 2023-03-09 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263498B (es) 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
AR039329A1 (es) 2002-04-26 2005-02-16 Lilly Co Eli Derivados de triazol, antagonistas de receptor de taquicinina
CA2484188C (en) 2002-04-26 2010-11-09 Eli Lilly And Company Tachykinin receptor antagonists
JP2004250329A (ja) * 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EA008881B1 (ru) 2003-10-24 2007-08-31 Эли Лилли Энд Компани Новые кристаллические формы {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1h-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Ｔｈ１型アレルギー疾患治療用組成物
DE102005006217B4 (de) * 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
WO2007096782A2 (en) 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compositions for disorders associated wtth metachromatic cell activation
EP2121610B1 (en) 2006-12-20 2014-04-02 Eli Lilly & Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
JP6644328B2 (ja) 2013-02-28 2020-02-12 ロート製薬株式会社 アトピー性疾患の発症又は重症化リスクの評価法
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
CA2915474A1 (en) * 2013-06-24 2014-12-31 Tigercat Pharma, Inc. Use of nk-1 receptor antagonist serlopitant in pruritus
JP6891385B2 (ja) * 2015-03-04 2021-06-18 バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． トラジピタントによる治療方法
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness

Also Published As

Publication number Publication date
IL272949A (en) 2020-04-30
AU2018331267B2 (en) 2024-03-07
JP2020533381A (ja) 2020-11-19
AU2018331267A1 (en) 2020-04-16
US20210062262A1 (en) 2021-03-04
EP3681505A1 (en) 2020-07-22
KR20200054232A (ko) 2020-05-19
US11549147B2 (en) 2023-01-10
WO2019055225A1 (en) 2019-03-21
CN111093671A (zh) 2020-05-01
MX2020002852A (es) 2020-07-22
BR112020004964A2 (pt) 2020-09-15
JP7347743B2 (ja) 2023-09-20
RU2020112222A (ru) 2021-10-13
CA3073998A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
CL2020000655A1 (es) Tratamiento mejorado de dermatitis atópica con tradipitant.
CL2019002824A1 (es) Anticuerpos anti-lag3.
CY1123065T1 (el) Ανασυνδυασμενα προβιοτικα βακτηριδια
ECSP17029371A (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
DOP2016000224A (es) Tratamientos combinados con anticuerpos anti-cd38
DOP2017000025A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
TWD174683S (zh) 戒指
TWD179056S (zh) 充電器
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
TWD173737S (zh) 肌肉鍛鍊機器
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
CL2017002238A1 (es) Método de tratamiento con tradipitant
ECSDI14032133S (es) Configuración aplicada a un refrigerador
AR106133A1 (es) Métodos para el tratamiento de la epilepsia
TWD171584S (zh) 自動出入閘門
CO2017000367A2 (es) Producción microbiana de dioles grasos
BR112016015881A2 (pt) Tecnologia inédita de adcc baseada em biologia sintética
CL2016000672A1 (es) Bacteria aislada del género streptomyces
CL2018000941A1 (es) Regulación del uso de nitrógeno
TWD179337S (zh) 管配件
TWD180363S (zh) 水龍頭
UA114708U (uk) Тяговий привід електробуса
AU366358S (en) Laptop case
TWD177062S (zh) 按摩器